18:36

Breakthrough in Bladder Cancer: FDA approval - Enfortumab Vedotin + Pelbrolizumab with Dr.Tom Powles

6:06

Treatment Options for Patients Not Eligible for the EV/Pembrolizumab Regimen

23:56

Bladder Cancer Treatment Algorithm Discussion with Drs. Karine Tawagi and Sia Daneshmand

15:41

How Muscle Invasive Bladder Cancer Patients Managed their Initial Diagnosis and Decided on Treatment

2:17

Will enfortumab vedotin and pembrolizumab be the new SOC in urothelial cancer?

32:11

What is New in Bladder Cancer Treatment and Research?

11:29

Enfortumab Vedotin Plus Pembrolizumab: Results of the EV-302 Trial With Thomas Powles, MD

11:44

Bladder Cancer Risk Stratification: Moving from the Old to the New